Text stringlengths 636 34.6k |
|---|
Drug A is Abaloparatide. Drug B is Acebutolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Acebutolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Aldesleukin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Aldesleukin is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Aliskiren. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Aliskiren. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Ambrisentan. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Ambrisentan. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmeno... |
Drug A is Abaloparatide. Drug B is Amifostine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amifostine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Amiloride. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amiloride is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Amiodarone. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amiodarone is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Amlodipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amlodipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Amobarbital. The severity of the interaction is moderate. Amobarbital may increase the hypotensive activities of Abaloparatide. The use of barbiturates may increase hypotension. 1,2 Therefore, the concomitant administration of barbiturates and hypotensive agents may lead to dangerous ... |
Drug A is Abaloparatide. Drug B is Amphotericin B. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amphotericin B is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe... |
Drug A is Abaloparatide. Drug B is Amyl Nitrite. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Apomorphine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Apomorphine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Aripiprazole lauroxil. The severity of the interaction is minor. Aripiprazole lauroxil may increase the hypotensive activities of Abaloparatide. Aripiprazole may cause orthostatic hypotension through antagonism of the α1-adrenergic receptor. 3,2,4 Cases of orthostatic hypotension, pos... |
Drug A is Abaloparatide. Drug B is Aripiprazole. The severity of the interaction is minor. Aripiprazole may increase the hypotensive activities of Abaloparatide. Aripiprazole may cause orthostatic hypotension through antagonism of the α1-adrenergic receptor. 3,2,4 Cases of orthostatic hypotension, postural dizziness, a... |
Drug A is Abaloparatide. Drug B is Arsenic trioxide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of se... |
Drug A is Abaloparatide. Drug B is Atenolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Atenolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Avanafil. The severity of the interaction is minor. The risk or severity of hypotension can be increased when Avanafil is combined with Abaloparatide. The subject drug is a phosphodiesterase 5 inhibitor which can lower blood pressure. 1 The affected drug can cause hypotension, particu... |
End of preview. Expand in Data Studio
No dataset card yet
- Downloads last month
- 3